Insufficient Evidence For Lipid Disorders Screening in Children
The U.S. Preventive Services Task Force (USPSTF) has concluded that there is insufficient evidence to assess the benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. The report is published in JAMA.
High levels of LDL-C, non-HDL-C and triglycerides and low levels of HDL are associated with risk of cardiovascular diseases in adults. The National Health and Nutrition Examination Survey (NHANES) estimates that 7.8 percent of children between 8 to 17 years of age have elevated levels of total cholesterol and 7.4 percent of adolescents between 12 to 18 years have elevated LDL-C. Theoretically speaking, screening for lipid disorders in children could lead to early identification and treatment.
However, the USPSTF has reviewed the evidence and has found inadequate evidence on the quantitative difference in diagnostic yield between universal and selective screening for familial hypercholesterolaemia or multifactorial dyslipidaemia.
See also: New Guidelines For Using Nonstatin Cholesterol-Lowering Drugs
The USPSTF was able to find adequate evidence from short term trials that pharmacotherapy interventions could reduce levels of LDL-C and TC in children with familial hypercholesterolaemia. However, there was inadequte evidence to address whether such treatment could led to a reduced incidence of premature cardiovascular disease. There was also inadequate evidence with respect to the association between changes in intermediate lipid outcomes or noninvasive measures of atherosclerosis in children and adolescents' incidence of mortality. Similarly, there was inadequate evidence on the benefits of lifestyle modification or pharmacotherapy interventions in children and adolescents with multifactorial dyslipidaemia.
Image Credit: Wikimedia Commons
Published on : Tue, 9 Aug 2016
The CNAP® Monitor represents the next generation of noninvasive patient monitoring by merging the advantages of noninvasive, risk‐free methods with the benefits of continuity in the same accuracy as invasive standards. The advanced parameter set enables...
The Task Force® Monitor is the all‐in‐one workstation for continuous noninvasive hemodynamic and autonomic assessment. It is the state‐of‐the‐art diagnostic tool to study syncope and autoregulation of blood pressure and has further established as an...